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THIS study compares the signal transduction pathway
which  leads  to  the  upregulation  of  intercellular
adhesion molecule-1 (ICAM-1) expression with that of
the  increase  in  the  expression  of  inducible  nitric
oxide synthase (iNOS) protein and activity caused by
endotoxin  in  cultured  J774.2  macrophages.  Treat-
ment of J774.2  cells with lipopolysaccharide E. coli
(LPS) induced a concentration-dependent increase in
the expression of ICAM-1 on the cell surface within
4h and an increase in iNOS protein and activity  at
24h.  The  upregulation  of  ICAM-1  expression  on
J774.2 macrophages caused by LPS was significantly
inhibited by pretreatment of the cells with inhibitors
of the activation of the nuclear transcription factor
NF-k B,  such  as  L-1-tosylamido-2-phenylethylchlor-
omethyl ketone (TPCK), pyrrolidine dithiocarbamate
(PDTC), rotenone or calpain inhibitor I, but not by
the tyrosine kinase inhibitors, tyrphostin AG126 or
genistein. In contrast, genistein or tyrphostin AG126
also  prevented  the  induction  of  iNOS  protein  and
activity in J774.2 macrophages elicited by LPS. Thus,
the increase in the expression of ICAM-1 on J774.2
macrophages by endotoxin involves the activation of
NFk B, but not of protein tyrosine kinase.
Key words: Inflammation,  ICAM-l,  iNOS,  NF-k B,  Protein
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Introduction
Intracellular adhesion molecule-1 (ICAM-1; CD54) is a
90-kDa inducible cell surface glycoprotein that pro-
motes  leukocyte  adhesion  in  inflammatory  condi-
tions.1,2 Analysis  of  ICAM-1  complementary  deoxy-
ribonucleic acid sequence revealed it to be a member
of the immunoglobulin gene superfamily.3 ICAM-1 is
expressed basally at low levels on many  cell types,
including  endothelial cells, macrophages, myocytes,
and  vascular  smooth  muscle  cells,4–7 but  can  be
induced to high levels by stimulation with lipopoly-
saccharide  (LPS),  phorbol  ester,  or  inflammatory
cytokines, such as tumour necrosis factor-a (TNF-a )
or interleukin-1b (IL-1b ). For that concerning cells of
the mono-myelocytic lineage, ICAM-1 expression on
the plasma membrane of macrophages is higher than
that measured on circulating monocytes.8 Nonethe-
less, ICAM-1 is not only a marker of differentiation,
and its expression can also be up-regulated following
cell activation, such as after treatment with IL-1b of
U-937 cells or of murine macrophages.9 The second
messenger  pathways  responsible  for  ICAM-1  induc-
tion are poorly understood, although there is some
evidence that activation of protein kinase C may be
involved at least in the upregulation observed on the
endothelial cell surface after treatment with TNF-a .10
In  addition, a  specific  binding  site  for  the  nuclear
transcription factor-k B (NF-k B) has been detected in
the promotor region of the ICAM-1 gene.11 From the
functional point of view, endothelial ICAM-1 mediates
the interaction between extravasating leukocyte and
the endothelium of post-capillary venules by binding
to the CD11/CD18 complex.12 In monocyte/macro-
phages,  surface  ICAM-1  mediates  the  process  of
antigen presentation as well as the interaction with
cell  types  other  than  endothelial  cells,  such  as
chondrocytes of the rheumatoid joint.13
Nitric oxide (NO) is a vasodilator autacoid which is
produced by  NO synthase from  L-arginine in  many
mammalian cells.14 NO has many diverse biological
functions in the cardiovascular, nervous and immune
systems. Once formed, NO diffuses to adjacent cells
where it activates soluble guanylate cyclase, resulting
in the formation of cyclic guanosine monophosphate,
which  in  turn  mediates  many,  but  not  all,  of  the
biological effects of NO. At least three isoforms of NO
synthase  have  been  cloned.  The  NO  synthase  in
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constitutively,  while  activation of  macrophages and
other cells with proinflammatory cytokines (e.g. TNF-
a , IL-1b ) or endotoxin (LPS) results in the expression
of an inducible isoform of NO synthase (iNOS), which
is functionally independent of changes in intracellular
calcium.15 The iNOS gene from murine macrophages
has  been  cloned  and  characterized,16 and  there  is
evidence  that  activation  of  protein  tyrosine  kinase
and  of  the  nuclear  transcription  factor  NF-k B  is
involved in the intracellular signal transduction path-
way leading to the expression of this enzyme.17–19
An  enhanced  formation  of  NO  following  the
induction  of  iNOS  by  LPS  in  macrophages  and
vascular smooth muscle cells contributes importantly
to the circulatory failure (hypotension) and multiple
organ dysfunction  syndrome associated with  septic
shock.15,18,19 Moreover, during sepsis the infiltration
of leukocytes plays a pivotal role in tissue damage. For
instance, septic shock results in an early accumulation
of polymorphonuclear leukocytes in  the liver (after
3h),  which is followed  by  an  infiltration  of  mono-
nuclear phagocytes (after 30h). There is evidence that
that the expression of ICAM-1 may contribute to the
influx of leukocytes during septic shock and, there-
fore,  play  a  role  in  tissue  damage  during  septic
shock.20 Interestingly, circulating levels of ICAM-1 are
higher in patients with septic shock than in patients
with severe sepsis or sepsis without hypotension.21
In  the  present  study,  we  used  cultured  J774.2
macrophages to study  the signal  transduction path-
way,  which  leads  to  the  upregulation  of  ICAM-1
expression by endotoxin and compared it with the
one leading to an induction of iNOS.
Methods
Induction of nitrite formation by endotoxin in
cultured macrophages
The mouse macrophage cell line J774.2 was cultured
in  Dulbecco’s  modified  Eagle’s  medium  (DMEM)
supplemented  with  L-glutamine  (3.5mM)  and  10%
foetal  calf  serum.18 Cells  were  cultured  in  96-well
plates with 200m l culture medium until they reached
confluence. To induce  iNOS  in  macrophages, fresh
culture medium containing Escherichia coli lipopoly-
saccharide  (LPS,  1m g/ml;  serotype,  0127:B8)  was
added.  Nitrite  accumulation  in  the  cell  culture
medium was measured after 24h. The following drugs
were  added to  cells  30min  before  LPS:  tyrphostin
AG126  (30m M),  genistein  (100m M),  rotenone
(30m M),  L-1-tosylamido-2-phenylethylchloromethyl
ketone (TPCK; 30m M),  pyrrolidine dithiocarbamate
(PDTC;  25m M),  calpain  inhibitor  I  (30m M),  anti-
inflammatory  cytokines  such  as  interleukin-4  (IL-4;
100ng/ml), interleukin-10 (IL-10; 100ng/ml) or inter-
leukin-13  (IL-13;  100ng/ml). The  concentrations of
compounds or cytokines were chosen from previous
studies.18,19,26 The amount of nitrite, an indicator of
NO  synthesis,  in  the  supernatant  of  J774.2  was
measured by the Griess reaction22 by adding 100m l
of  Griess  reagent  to  100-m l  samples  of  unfiltered
serum or supernatant. The optical density at 550nm
(OD550)  was  measured  using  a  Molecular  Devices
microplate  reader  (Richmond,  CA,  USA).  Nitrite
concentrations were calculated by comparison with
OD550  of  standard solution  of  sodium  nitrite  pre-
pared  in  control  culture  medium.  Mitochondrial
respiration, an indicator of cell viability, was assessed
by  the  mitochondrial-dependent reduction  of  MTT
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide] to formazan.23 Cells in 96-well plates were
incubated (37°C) with MTT (0.2mg/ml for 60min).
Culture medium was removed by aspiration and cells
solubilized in dimethylsulfoxide by measurement of
OD550 using a Molecular Devices microplate reader.
Formazan production was expressed as a percentage
of the values obtained from untreated cells.
Western (immuno) blot analysis (iNOS)
J774.2 macrophages were cultured in six-well plates
(37°C) and treated for 24h with fresh medium alone
(control)  or  medium  containing  LPS  (1  m g/ml)  to
induce  iNOS.  To  assess  the  effects  of  tyrphostin
AG126, genistein, rotenone, PDTC, TPCK or calpain
inhibitor I on the expression of iNOS protein induced
by immunostimulants, compounds were added to the
cells  30min  prior  to  LPS.  After  24h,  cells  were
washed with phosphate-buffered saline (PBS; pH 7.4)
and incubated (5min) with 1ml of extraction buffer
(pH 7.4) consisting of 50mM Tris–HCl, 10mM EDTA,
1%  (v/v) Triton  X-100,  and  the  protease  inhibitors
pepstatin  A  50m M,  leupeptin  0.2mM  and  phenyl-
methylsulphonylfluoride  1mM. The cell extract was
boiled for 10min with gel-loading buffer (Tris, 20mM;
EDTA,  2mM;  SDS,  2%  (w/v);  glycerol,  20%  (v/v);
2-mercaptoethanol,  10%  (v/v);  bromophenol  blue,
2mg/ml; pH 6.8) in a ratio of 1:1 (v/v). Samples were
centrifuged at 10000g for 2min before being loaded
onto gradient gels  (7.5%  SDS  gel)  and subjected to
electrophoresis (1h at 150V). The separated proteins
were  transferred  to  nitrocellulose  (Bio-Rad;  1h  at
200V). After transfer to nitrocellulose by electropho-
resis, the membranes were primed over night at 4°C
with  a  polyclonal  antibody  raised  to  macrophage
iNOS developed in rabbits (a generous gift from Dr
Claire  Bryant,  William  Harvey  Research  Institute,
UK).24The blots were then incubated with anti-rabbit
IgG linked to horseradish peroxidase. All antibodies
were used at a 1:5000  dilution. Horseradish perox-
idase-conjugated secondary antibody was then added
and blots developed using an enhanced horseradish
peroxidase/luminol  chemiluminescence  reaction
(ECL Western blotting detection reagents, Amersham
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X-ray film for 30–60s.
Measurement of ICAM-1 and CD11b levels by
fluorescence-activated cell sorter (FACS)
analysis
J774.2 macrophages were cultured in six-well plates
as  described  above  and,  after  they  reached  con-
fluence, were washed and incubated with or without
LPS (0.01–10mg/ml) for 4 or 24h. At the end of the
incubation period, cells  were washed and removed
with non-enzymatic dissociation medium and pelleted
by centrifugation at 400g for 15min at 4°C. Subse-
quently,  cells  were  seeded  in  96-well  flat-bottom
plates in 20m l of PBS supplemented with 0.2% bovine
serum albumin (BSA); non-specific sites were blocked
by adding 20m l of human IgG (15mg/ml) prior to the
addition  of  20m l  of  a  rat  anti-mouse  ICAM-1
(16m g/ml) or rat anti-mouse CD11b (16m g/ml) mono-
clonal  antibody.  Control  wells  received  an  equal
amount of rat IgG. After 1h at 4°C, cells were washed
twice with PBS/+0.2%BSA and incubated with 40m l
of diluted (1:40) F(ab9 )2 fragment of goat anti-rat IgG
antibody  conjugated  to  fluorescein  isothiocyanate
(FITC).  After  a  further  45min  at  4°C,  cells  were
washed, resuspended in 200m l PBS/+0.2% BSA and
fixed with an equal volume of 2% paraformaldehyde.
FACS analysis was performed within 5 days using a
FACScan  II  analyser  (Becton-Dickinson,  Mountain
View, CA) with an air-cooled 100mW argon ion laser
tuned to 488 nm and Consort 32 computer running
Lysis II software (Becton-Dickinson). At least 10000
events were analysed for each labelling.  Data were
analysed as units of fluorescence measured in the FLl
channel, corrected for control binding (rat IgG), and
converted to the number  ofmAb  molecules  bound
per cell with reference to microbeads labelled with
standard molecules  of  FITC  (Flow  Cytometry  Stan-
dards Corp., Research Triangle Park, NC).25
Materials
Bacterial  lipopolysaccharide  (E.  coli serotype
0.127:B8),  phosphate-buffered saline (PBS),  Dulbec-
co’s  modified  Eagle’s  medium,  foetal  calf  serum,
L-glutamine,  MTT,  pepstatin A,  leupeptin,  glycerol,
2-mercaptophanol,  phenylmethylsulphonylfluoride
(PMSF),  Bradford  reagent,  bovine  serum  albumine,
rotenone,  L-1-tosylamido-2-phenylethylchloromethyl
ketone (TPCK), pyrrolidine dithiocarbamate (PDTC),
human IgG, Triton X-100, Trizma base, EDTA, bromo-
phenol blue, sodium dodeyl sulphate (SDS), sulphani-
lamide,  naphthylethylenediamide,  phosphoric  acid,
non-enzymatic  dissociation medium,  and  anti-rabbit
IgG antibody were obtained from Sigma Chemical Co.
(Poole,  Dorset, UK).  Pure  nitrocellulose  membrane
(0.45 m m) and filter paper were purchased from Bio-
Rad (Hertfordshire, UK). The following antibodies (AB)
were purchased from Serotec (Oxford, UK): rat anti-
mouse ICAM- 1, monoclonal rat anti-mouse CD11b and
monoclonal  FITC-conjugated  donkey  anti-rat  IgG.
Tyrphostin  AG126  [(3-hydroxy-4-nitrobenzylidine)
malononitrile  or  a-cyano-(3-hydroxynitro)cinnamoni-
trile], genistein [4,5,7-trihydroxy-isoflavone] and cal-
pain  inhibitor  I  (N-acetyl-leu-leu-norleucinal)  were
from Calbiochem (Nottingham, UK). Murine recombi-
nant IL-4 and human recombinant IL-10 and IL-13 were
a generous gift of Dr P. Grint (Schering-Plough, USA).
Statistical evaluation
Results shown are mean±S.E.M. from triplicate deter-
minations  (wells)  from  three separate experiments.
One-way  or  two-way  analysis  of  variance  (ANOVA)
followed by, if appropriate, Bonferroni multiple range
test was used to compare means between groups. A P
value less than 0.05 was considered to be statistically
significant.
Results
LPS-induced ICAM-1 and iNOS expression in J774.2
macrophages
A constitutive expression of ICAM-1 and CD11b was
found  on the plasma membrane of  cultured  J774.2
macrophages (Fig. 1a,b). Incubation of J774.2 macro-
phages with 1m g/ml LPS resulted, within 4h, in an
upregulation  of  ICAM-1  expression  without  further
increase at the 24-h time-point (Fig. 1a). LPS-induced
4-h ICAM-1 expression was concentration dependent
(Fig. 1c). In contrast, treatment of macrophages with
different  concentrations  of  LPS  did  not  affect  the
expression of CD11b (Fig. 1b,d). Activation of J774.2
macrophages with endotoxin resulted within 24h in a
significant increase in nitrite in the cell supernatant
(Table  1).  This  was  mirrored  by  appearance  of  a
130-kDa protein which was recognized by a specific
antibody to iNOS (Fig. 3, lane B).
In subsequent experiments, designed to elucidate
similarities  or differences  in  the  LPS-induced signal
transduction pathways which lead to the expression
of iNOS protein and activity, and to the upregulation
of ICAM-1 in J774.2 macrophages, only 1m g/ml of LPS
for  4h  (ICAM-1  expression)  or  24h  (expression  of
iNOS protein and activity) was used.
Involvement of tyrosine kinase
Pretreatment of J774.2 macrophages with the protein
tyrosine kinase inhibitors genistein (100m M) or tyr-
phostin AG126  (30m M)  significantly  attenuated the
expression  of  iNOS  protein  and  the  formation  of
nitrite elicited by LPS (Table 1, Fig.  3). In contrast,
neither inhibitor prevented LPS upregulation of the
membrane-bound ICAM-1 (Fig. 2a).
ICAM-1 and iNOS expression in macrophages
Mediators of Inflammation · Vol 8 · 1999 79Involvement of NF-k B
Activation of NF-k B by LPS leads to the induction of
iNOS in macrophages, and involves the formation of
reactive  oxygen  intermediates.18 Accordingly,  pre-
treatment of J774.2 cells with PDTC (25m M) or the
antioxidant rotenone (30m M) prevented the increase
in the formation of nitrite and the expression on iNOS
protein caused by endotoxin (Table 1). Both PDTC
and rotenone also attenuated the expression of ICAM-
1  in  a  concentration-dependent  manner  (Fig.  2b).
Treatment of J774.2 cells with TPCK, a cysteine and
serine protease inhibitor, or calpain inhibitor I prior
to endotoxin, significantly attenuated the increase in
the formation of nitrite and the expression of iNOS
protein caused by LPS (Table 1, Fig. 3). In addition,
the  increase in  the  expression  of  ICAM-1  was  also
concentration-dependently attenuated by both TPCK
or calpain inhibitor I (Fig. 2c). It is noteable that none
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FIG. 1. Time course of the expression of (a) ICAM-1 and (b) of CD11b by J774.2 macrophages activated with endotoxin. J774.2
cells were incubated in the absence (solid squares) or presence (open squares) of LPS (1m g/ml) for 0, 4 or 24h, respectively.
Endotoxin caused a concentration-dependent increase in the expression of (c) ICAM-1 but not (d) of CD11b by J774.2 cells.
Macrophages were treated with vehicle (C, saline; solid columns) or LPS (0.01–10m g/ml; open columns) for 4h. At the end of
experiments, adhesion molecule expression on the plasma membrane was quantified by FACS analysis. Data are expressed
as  mean±S.E.M.  from  triplicate determinations (wells)  from  three  separate  experimental days (n=9).  *P<0.05 represents
significant difference when compared to control values.
Table 1. Effect of tyrphostin AG126, genistein, rotenone, L-l-
tosylamido-2-phenylethylchloromethyl ketone  (TPCK),  pyr-
rolidine dithiocarbamate (PDTC) or calpain inhibitor I on the
increase in the formation of nitrite in supernatant of J774.2
macrophages activated with LPS (1m g/ml) for 24h
Compound Concentration (m M) Nitrite (m M)
Control – 1.81 ± 0.4
LPS (1m g/ml) – 48.4 ± 3.6
+ tyrphostin AG126 30 17.5 ± 2.8*
+ genistein 100 13.4 ± 4.6*
+ rotenone 30 10.2 ± 3.8*
+ PDTC 25 8.6 ± 3.7*
+ TPCK 30 16.5 ± 2.3*
+ calpain inhibitor I 30 14.3 ± 3.1*
Data are expressed as mean±S.E.M. from triplicate
determinations (well) from three separate experimental
days (n=9). *P<0.05 represents significant difference when
compared to LPS-control.of the drugs used modified the constitutive expres-
sion of ICAM-1 (Fig. 2a–c).
Incubation of J774.2 macrophages with LPS alone
caused a small (~20%)  reduction in  cell  viability at
24h,  as measured  by  formazan  formation,  with no
effect at the 4-h time-point. Incubation of J774.2 cells
with  the  drugs  used  did  not  result  in  a  significant
reduction in cell viability. Similarly, none of the drugs
used attenuated the reduction in cell viability caused
by LPS at 24h (Table 2).
Anti-inflammatory cytokines
To  test  whether  anti-inflammatory  cytokines  pre-
vented the upregulation of membrane-bound ICAM-1
on macrophages, J774.2 cells were treated with IL-4,
IL-10 or IL-13 (all 100ng/ml) prior to LPS. None of
these cytokines affected either basal or LPS-induced
increase  in  the  expression  of  ICAM-1  on  the  cell
surface  of  J774.2  macrophages.  In  contrast,  and
confirming previous studies,26,27 IL-4, IL-10 or IL-13
significantly attenuated the increase in the formation
of  nitrite in the supernatant caused by LPS at 24h
(Fig. 4, Table 2).
Discussion
ICAM-1 expression at the plasma membrane of several
cell  types  is  related  not  only  as  marker  of  cell
differentiation, but also to the degree of cell activa-
tion.  Few  studies  have  investigated  the  signalling
pathways leading to the upregulation  of  ICAM-1 in
mono-myelocytic  cells.  Using  J774.2  macrophages
which closely mimic primary macrophages in many
aspects,26 we have compared the signal transduction
pathway  leading  to  the  upregulation  of  ICAM-1
expression with that of the increase in the expression
of iNOS protein and activity caused by endotoxin.
The induction of iNOS protein and activity caused
by  wall  fragments  of  Gram-negative  (endotoxin),
Gram-positive (lipoteichoic acid, peptidoglycan) bac-
teria or pro-inflammatory cytokines, such as IL-1b in
cultured cells (e.g. macrophages), involves the phos-
phorylation of  tyrosine residues in  proteins, and is
therefore prevented by the tyrosine kinase inhibitors
genistein,  erbstatin  and  tyrphostin AG126.28–30 We
confirm here  that two structurally  distinct  tyrosine
kinase inhibitors, genistein (competitive inhibitor at
ICAM-1 and iNOS expression in macrophages
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FIG.  2.  Effect  of  (a)  tyrphostin  AG126  (tyr  AG126)  or
genistein,  (b)  rotenone  or  pyrrolidine  dithiocarbamate
(PDTC),  (c)  L-1-tosylamido-2-phenylethylchloromethyl
ketone (TPCK) or calpain inhibitor I (cal-I) on the increase in
the expression of ICAM-1 on the cell plasma membrane of
J774.2  macrophages  activated  with  LPS  (1m g/ml)  for  4h.
J774.2 cells were incubated with the drugs in the absence
(open columns) or presence (hatched columns) of LPS. Data
are  expressed  as  mean±S.E.M.  from  triplicate  determina-
tions  (wells) from  three separate  experimental days (n=9)
and are expressed as D ICAM-1, the basal value (without LPS
or  drugs)  being subtracted.  *P<0.05 represents  significant
difference when compared to LPS-controls (solid column).
Table 2. Effect of interleukin-4, interleukin-10 or interleukin-
13 on the increase in the formation of nitrite in supernatant of
J774.2 macrophages activated with LPS (1m g/ml) for 24h
Compound Dose (m g/ml) Nitrite (m M)
Control – 1.8 ± 0.4
LPS 1 52.4 ± 2.3
+ interleukin-4 0.1 23.5 ± 4.6*
+ interleukin-13 0.1 26.8 ± 3.3*
+ interleukin-10 0.1 43.4 ± 3.8*
Data are expressed as mean ± S.E.M. from triplicate
determinations (well) from three separate experimental
days (n=9). *P<0.05 represents significant difference when
compared to LPS control.the  ATP-binding  site)  or  tyrphostin  AG126  (com-
petitive inhibitor at the substrate binding site), used at
selected and validated concentrations,31,32 inhibit the
expression of iNOS caused by LPS, clearly showing
that tyrosine phosphorylation plays an important role
in  the  signal  transduction  pathway  leading  to  the
expression of iNOS by LPS in J774.2 macrophages. In
contrast,  treatment  of  J774.2  macrophages  with
genistein  or  tyrphostin AG126  did  not  prevent  the
LPS-induced upregulation of the expression of mem-
brane-bound  ICAM-1.  A  similar  finding  has  been
described  in  endothelial  cells. The  tyrosine  kinase
inhibitors, genistein and tyrphostin AG1288 had no
effect  on  the  TNF-a -induced  increase  in  ICAM-1
expression on cultured EA.hy926 endothelial cells at
4h after TNF-a , but significantly increased the expres-
sion of ICAM-1 at 24h.33 In contrast, genistein and AG
1288 significantly inhibited TNF-a -induced upregula-
tion of ICAM-1 expression on A549 epithelial cells at
4h  after  TNF-a ,  but  had  no  effect  on  ICAM-1
expression at 24h.34 These results  suggest  that the
effects (increase, decrease or no effect)  of  tyrosine
kinase inhibitors on the TNF-a - or LPS-induced upre-
gulation of ICAM-1 expression on the plasma mem-
brane  depend  on  the  cell  type  and  the  time  of
exposure  to  immunostimulants.  Our  data  demon-
strated that this pathway is unlikely to be activated in
J774.2 cells to induce this adhesion molecule.
The expression of inducible genes including iNOS
are  largely  controlled  by  proteins,  such  as  NF-k B,
which activate transcription.17,35 NF-k B is itself acti-
vated by the exposure of cells to endotoxin or TNF-a ,
IL-l,  IL-2  or  phorbol  12-myristate  13-acetate
(PMA).36–39 The  most  frequent  form  of  NF-k B  is  a
heterodimer composed of two DNA-binding proteins,
namely NF-k B1 (or p50) and RelA (or p65), although
other dimeric combinations also exist.40 Under phys-
iological  conditions,  NF-k B  is  held  (in  an  inactive
form) in the cytoplasm by the inhibitory protein Ik B-
a , which avidly binds to most heterodimers including
the  NF-k B1/RelA  heterodimer.  Activation  of  NF-k B
involves the release of the inhibitory subunit  Ik B-a
from  a  cytoplasmic  complex,  which  Ik B  forms
together with the DNA-binding subunit RelA and NF-
k B141,42 and, hence, activation of NF-k B allows NF-
k B to translocate to the nucleus and to induce the
expression  of  specific  genes.43,44 The  activation  of
iNOS  in  macrophages  caused  by  LPS  or  LTA  is
diminished by inhibitors of the activation of NF-k B,
such as PDTC, TPCK, or calpain inhibitor I.18,30,46,47
However,  the  proteolytic  degradation  of  Ik B-a is
inhibited  with  some  selectivity  by  the  cysteine
protease inhibitor calpain inhibitor I, but not by other
inhibitors of  serine and cysteine proteases, such as
chymostatin  or  leupeptin.48 There  is  evidence  that
activation of the promotor of ICAM-1 by cytokines on
endothelial cells critically relies on the transcription
factor NF-k B.49 Six potential NF-k B sites have been
identified in the ICAM-1 59 -flanking sequence and first
intron.50,51 We show that PDTC which inhibits NF-k B
activation,52 not  only  prevented  the  expression  of
iNOS  protein  and  activity  (nitrite),  but  also  the
upregulation of ICAM-1 expression caused by LPS in
J744.2  cells.  In  addition,  the  cysteine  and  serine
protease inhibitors TPCK or calpain inhibitor I, which
inhibit  Ik B  protease,48 prevented  the  LPS-induced
expression of iNOS protein and activity as well as the
H. Ruetten et al.
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FIG.  3.  Effect  of  tyrphostin  AG126  (30m M;  lane  H)  or  genistein  (100m M;  lane  G),  rotenone  (30m M;  lane  F),  pyrrolidine
dithiocarbamate (25m M; lane E), calpain inhibitor I  (30m M; lane D)  or  L-1-tosylamido-2- phenylethylchloromethyl ketone
(30m M; lane C) on the expression of iNOS protein in J774.2 macrophages caused by LPS (1m g/ml; lane B) within 24h, as
determined by Western (immuno)blot analysis. There was no iNOS protein detectable by the specific antibody against iNOS
protein in unstimulated control macrophages (lane A). This immunoblot is representative for three separate experiments.
FIG. 4. Effect of interleukin-13 (IL-13), interleukin-10 (IL-10) or
interleukin-4 (IL-4) on the increase in the expression of ICAM-
1  on  the  cell  plasma  membrane  of  J774.2  macrophages
caused  by  endotoxin.  J774.2  cells  were  incubated  in  the
absence (open columns) or presence (hatched columns) of
LPS (1mg/ml) with IL-13, IL-10 or IL-4 (all 100ng/ml) for 4h.
At 4h after LPS ICAM-1 expression was monitored by FACS
analysis. Data are expressed as mean±S.E.M. from triplicate
determinations  (wells)  from  three  separate  experimental
days (n=9). *P<0.05 represents significant difference when
compared to LPS controls (solid column).upregulation of ICAM-1 expression. This implies that
activation of Ik B protease, known to be involved in
the  induction  of  iNOS,  is  also  important  in  the
upregulation of ICAM-1 expression caused by LPS on
J774.2 macrophages.
One of the determinantes of NF-k B activation is the
redox status of the cell,53 which is determined by the
concentration of reactive oxygen species, including
superoxide,  hydrogen  peroxide  or  hydroxyl  radi-
cals.52 There  is  evidence  that  cytokines  and  LPS
increase  the  formation  of  cellular  reactive  oxygen
intermediates  by  causing  an  alteration  of  electron
flow  in  the  mitochondria.53 We  show  that  the
antioxidant  rotenone  prevented  the  induction  of
iNOS protein and activity as well as the upregulation
of ICAM-1 expression caused by LPS. A similar finding
has  been  reported  with  the  potent  antioxidant
N-acetyl  cysteine  which  inhibits  the  induction  of
iNOS  protein  and  activity  caused  by  LPS  in  rat
peritoneal macrophages: this effect was linked to a
reduced  activation  of  NF-k B.55 Moreover,  N-acetyl
cysteine  also  inhibits  ICAM-1  mRNA  expression  in
HeLa  and  HaCaT  cells  after  exposure  to  ionizing
radiation, known to produce reactive oxygen inter-
mediates in mammalian tissues, by inhibition of the
activation  of  NF-k B.56 Thus,  reactive  oxygen  inter-
mediates, presumably by their ability to activate NF-
k B,  play  an  important  role  in  the  series  of  events
leading  to  the  expression  of  iNOS  and  ICAM-1
induced by LPS in these cells as well as in J774.2 cells,
as described here.
The anti-inflammatory cytokines IL-4, IL-10 or IL-13
have been reported to inhibit the LPS-induced forma-
tion of NO by cultured macrophages by preventing
the  induction  of  iNOS  protein  expression.26,27
Indeed,  we  confirm  in  this  study  that  all  three
cytokines, inhibited  the  induction  of  iNOS  protein
and  activity  caused by  LPS in  J774.2  macrophages.
Interestingly, IL-4, IL-10 or IL-13 neither affected basal
nor LPS-induced expression of ICAM-1 in these cells.
Therefore, there is some cell specificity in IL-4 effects
upon ICAM-1, since this cytokine directly increases
ICAM-1 levels  on other cell  types including  human
dermal fibroblasts57 and human umbilical vein endo-
thelial  cells.58 Like  IL-4,  IL-13  also  induces  ICAM-1
expression  in  unstimulated  human  mast  cells.45 In
contrast,  IL-10  and  IL-13  inhibit  the  IL-1-  or  IFN-
k -induced  expression  of  ICAM-1  in  human  mono-
cytes, human synovial fibroblasts and human endothe-
lial  cells.54,59,60 Thus,  the  effect  of  the
anti-inflammatory cytokines IL-4, IL-10 or IL-13 on the
expression of ICAM-1 depends on the cell system and
the stimulus employed for activation.
In  conclusion,  this  study  demonstrated  that
increase  in  ICAM-1  and  iNOS  expression  in  J774.2
macrophages by endotoxin involves reactive oxygen
intermediates, and the activation of NF-k B. In contrast
to  the  signal  transduction  pathway  leading  to  the
induction  of  iNOS,  activation  of  protein  tyrosine
kinase is not involved in the LPS-induced upregulation
of  ICAM-1  expression  in  J774.2  macrophages,  and
consequently  this  pathway  is  not  sensitive  to  anti-
inflammatory interleukins.
ICAM-1 and iNOS expression in macrophages
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